Trial Profile
Treatment of Advanced Gastrointestinal Adenocarcinoma in a Phase I/II trial with modified allogeneic MSC_apceth_111
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 29 Mar 2017
Price :
$35
*
At a glance
- Drugs Agenmestencel-T (Primary) ; Ganciclovir (Primary)
- Indications Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Pancreatic cancer
- Focus Adverse reactions; First in man
- Acronyms TREAT-ALL 1
- Sponsors Apceth Biopharma
- 25 Mar 2017 Status changed from suspended to discontinued.
- 02 Mar 2016 Status changed from recruiting to suspended as reported by European Clinical Trials Database record.
- 30 Mar 2015 New trial record